IP Library › Granted Patent US 11,143,663
Granted Patent B2
US 11,143,663 · App. 17/093,099 · Granted Oct 12, 2021

Slope spectroscopy standards

Inventors: Mark Salerno (Cranford, NJ); I-Tsung Shih (Basking Ridge, NJ); Craig Harrison (Basking Ridge, NJ)
Assignee: C Technologies, Inc.
G01N33/92G01N21/255G01N21/31G01N33/94G01N2021/3129G01N2201/1293
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,143,663
App. No.
17/093,099
Granted
Oct 12, 2021
Kind
B2
Abstract

The present invention relates generally to a slope spectroscopy standards and methods of making slope spectroscopy standards, specifically standards and methods of developing standards specifically for variable pathlength (slope) measurements.

Claims (8)

1. A method of making a slope spectroscopy standard for an antibody/drug combination of a particular ratio of drug to antibody comprising:

determining the antibody to drug ratio of the antibody/drug combination;

determining a concentration of first compound which absorbs light at a wavelength corresponding to the antibody by using variable path length spectroscopy;

determining a concentration of a second compound which absorbs light at a wavelength corresponding to the drug corresponding to the drug slope by using variable path length spectroscopy;

making a first compound/second compound standard by combining the first compound at a concentration with the slope corresponding to the antibody with the second compound at a concentration with the slope corresponding to the drug at a ratio corresponding to the antibody/drug combination.

2. The method of claim 1 , wherein the first compound is caffeine.

3. The method of claim 1 wherein the second compound is a colorant which absorbs light at a wavelength corresponding to the drug.

4. The method of claim 1 wherein the compound is a second microbead which absorbs light at a wavelength corresponding to the drug.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2025
From: C TECHNOLOGIES INC.
To: REPLIGEN CORPORATION
Reel/Frame 071004/0948 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2022
From: SALERNO, MARK; SHIH, I-TSUNG; HARRISON, CRAIG
To: C TECHNOLOGIES, INC.
Reel/Frame 059498/0177 →
Continuity (3)
Continuation 16445414 · Jun 19, 2019
Provisional Application 62762891 · May 24, 2018
Related Publication 20210055315A1 · Feb 25, 2021